Psychiatr. pro Praxi, 2002; 6: 281-283

Milnacipran v dlouhodobé léčbě deprese

doc. MUDr. Vladimír Pidrman Ph.D, MUDr. Klára Látalová, prof. MUDr. Jaroslav Bouček CSc
Psychiatrická klinika FN a LF UP, Olomouc

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, Látalová K, Bouček J. Milnacipran v dlouhodobé léčbě deprese. Psychiatr. praxi. 2002;3(6):281-283.

Autoři předkládají stručnou literární charakteristiku milnacipranu, druhého SNRI na našem trhu. Na základě jeho vlastností se pokoušejí stanovit profil nemocného vhodného pro léčbu milnacipranem. Ve druhé části předkládají vlastní zkušenosti s dlouhodobou léčbou milnacipranem, kdy prokazují dobrý terapeutický účinek a dobrou snášenlivost léku.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Basire S. Psychotropic drug directory 2000. Mark Alen Publishing, Ltd., Jesses Farm, 2001, 340 s.
    2. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychophramacol, 1996; (suppl. 11) 4: 10-14. Go to original source... Go to PubMed...
    3. Braunwald E. Harisson´s principles of internal medicine. McGraw-Hill Book Comp., New York, 1998: 2918 s.
    4. Clerc G, et al. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenalin inhibitor. Int Clin Psychopharmacol, 2001; 16: 1-7. Go to original source... Go to PubMed...
    5. Cozza KL, Armstrong SC. The cytochrome P450 systém. Drug interaction principles for medical practice. American Psychiatric Publishing, Inc., Washington, DC, 2001: 262 s.
    6. Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Springer, Berlin, 2001; 2258 s. Go to original source...
    7. Kasper S, Pletan Y, Solies A, Tournox A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with a major depression: a summary of clinical trials. Int Clin Psychopharmacol, 1996; 11 (4): 35-39. Go to original source... Go to PubMed...
    8. Moret C, Charveron M, Finberg JPM, Briley M. Biochemical profile of milnacipran, a potential fourth generation antidepressant drug. Neuropharmacology, 1985; 24: 1211-1219. Go to original source... Go to PubMed...
    9. Moret C, Briley M. In vivo study of monoamines neurotransmission by milnacipran. Brain Research Association Abstracts, 1996; 13: 35.
    10. Montgomery SA, et al. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol, 1996; (suppl. 4) 11: 47-51. Go to original source... Go to PubMed...
    11. Pidrman V. Deprese a kardiovaskulární onemocnění. Maxdorf, Praha, 2. rozšířené vydání, 2002: 48 s.
    12. Preskorn SH. Outpatient management of depression. Professional Communication, Inc, Caddo 1999: 256 s.
    13. Puech A, Montgomery SA, Prost JF, Briley M. Milnacipran, a new serotonin and noradrenalin reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol, 1997; 12: 99-108. Go to original source... Go to PubMed...
    14. Raboch J, Zvolský P, et al. Psychiatrie. Praha, Galén a Univerzita Karlova, Karolinum, 2001: 622 s.
    15. Rouet RH, et al. Comparative in vivo and in vitro study of the cardiac effect of milnacipran and imipramine. Fundam. Clin Pharmacol, 1989; 3: 237-224. Go to original source... Go to PubMed...
    16. Rouillon F, et al. Milnacipran efficacy in the prevention of recurent depression: a 12 month placebo - controlled study. Int Clin Psychopharmacol 2000; 15: 133-140. Go to original source... Go to PubMed...
    17. Shiloh R, Nutt D, Weizman A. Atlas of psychotropic pharmacotherapy, Martin Dunitz, London, 2000: 235 s.
    18. Stahl MS. Psychopharmacology of antidepressants. Martin Dunitz, London, 1997: 114 s.
    19. Spencer AM, Wilde MI. Milnacipran, a review of its use in depression. Drugs, 1998; 56 (3): 405-427. Go to original source... Go to PubMed...
    20. Stahl MS. Essential psychopharmacology of depression and bipolar disorder. Cambridge University Press, Cambridge, 2000; 176 s.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.